Taking people in Norvégia2/3. fázis
Imaging multiple myeloma patients in the REMNANT study with Fluciclovine PET/CT (FLUCIPET)
Key facts
- Where
- Oslo, NorvégiaSee the site
- Phase
- 2/3. fázis
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Where in Norvégia
- Oslo University Hospital HFOslo, NorvégiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Oslo University Hospital HF
- Trial code
- EU 2024-517095-38-00
- Record updated
- 2025. május 27.
- Original description
To detect the number of patients in the REMNANT study who are positive with Fluciclovine PET/CT and negative with FDG PET/CT and determine how this correlate to PFS and OSRead full original descriptionShow less
To detect the number of patients in the REMNANT study who are positive with Fluciclovine PET/CT and negative with FDG PET/CT and determine how this correlate to PFS and OS
Inclusion: Patients who have been enrolled in the REMNANT study Part 2 and who are eligible for FDG PET/CT.
Exclusion: Hypersensitivity to the active substance or to any of the excipients; Patients with renal impairment for whom an increased radiation exposure is possible, and the additional potential risk is considered not acceptable; Patients who do not sign the consent for any reason or do not accept the study premises.